RxDoctor Payments Data

Mercy Chandrasekaran, MD

Cardiovascular Disease · Milwaukee, WINPI 1417105750

Payments from drug & device makers

$1,844in general payments, 2019–2025

Across 22 payments — averaging $83.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Astellas Pharma US Inc$99
  • Novartis$71
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$46
  • Lantheus Medical Imaging, Inc.$39
  • Heartflow, Inc.$26
  • plus $19 from 1 others

What the payments were for

  • Travel & lodging$1,04557%
  • Food & beverage$69938%
  • Education$995%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,844 in reported general payments places this provider in the 55th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$175,490
Medicare patients
911
Services billed
2,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban289$421,471
Repatha SureclickEvolocumab101$81,323
EntrestoSacubitril/Valsartan50$67,807
XareltoRivaroxaban38$58,549
JardianceEmpagliflozin17$29,306
BrilintaTicagrelor28$19,688
Praluent PenAlirocumab17$14,289
Ranolazine ErRanolazine38$6,186
Potassium Chloride88$3,985
Metoprolol Succinate233$3,490
Atorvastatin Calcium249$3,000
Bumetanide51$2,386
Rosuvastatin Calcium135$1,886
Flecainide Acetate27$1,637
ClopidogrelClopidogrel Bisulfate110$1,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$71$67,80750 claims
Boehringer IngelheimJardiance$19$29,30617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →